TMP-SMX Dosing for Positive Wound Cultures
For wound infections with positive cultures, the appropriate TMP-SMX dosage depends on the type and severity of infection: for uncomplicated skin and soft tissue infections (SSTIs), use 1-2 double-strength (DS) tablets (160/800 mg) twice daily for 5-10 days; for complicated SSTIs or bone/joint infections, use 3.5-4.0 mg/kg of TMP component every 8-12 hours. 1
Dosing by Infection Type
Uncomplicated Skin and Soft Tissue Infections
- Standard outpatient dosing: 1-2 DS tablets (160/800 mg TMP/SMX) twice daily 1
- Duration: 5-10 days, individualized based on clinical response 1
- This applies to purulent cellulitis, abscesses requiring antibiotics, and wound infections without deep tissue involvement
Complicated Skin and Soft Tissue Infections
For hospitalized patients with deeper infections, surgical/traumatic wounds, major abscesses, or infected ulcers:
- Dosing: 3.5-4.0 mg/kg of TMP component every 8-12 hours (PO or IV) 1
- For an 80 kg adult, this equals approximately 2 DS tablets (320 mg TMP) every 8-12 hours
- Duration: 7-14 days based on clinical response 1
Bone and Joint Infections
- Osteomyelitis: 3.5-4.0 mg/kg TMP every 8-12 hours, often combined with rifampin 600 mg daily 1
- Septic arthritis: Same dosing as osteomyelitis 1
- Surgical debridement is mandatory alongside antibiotics
Critical Considerations
High-dose vs. standard-dose controversy: Research shows that higher doses (320/1600 mg twice daily) do not improve clinical outcomes compared to standard dosing (160/800 mg twice daily) for MRSA SSTIs, with both achieving approximately 73-75% clinical resolution 2. The standard dose is therefore preferred to minimize adverse effects while maintaining efficacy.
Coverage gaps: TMP-SMX provides excellent coverage for MRSA and many gram-positive organisms but does NOT cover β-hemolytic streptococci. For nonpurulent cellulitis where streptococci are likely, add a β-lactam (e.g., amoxicillin 500 mg three times daily) or use an alternative agent 1.
Surgical intervention: For abscesses and purulent collections, incision and drainage is the primary treatment. Antibiotics alone have a 60% failure rate versus 25% when combined with drainage 3. TMP-SMX should be considered adjunctive therapy, not monotherapy for drainable collections.
Special Populations and Adjustments
Renal impairment 4:
- CrCl >30 mL/min: Standard dosing
- CrCl 15-30 mL/min: Half the usual dose
- CrCl <15 mL/min: Not recommended
Pediatric dosing (>2 months): 40 mg/kg sulfamethoxazole and 8 mg/kg TMP per 24 hours, divided every 12 hours 4
Common Pitfalls
Using TMP-SMX for animal or human bites: TMP-SMX has poor anaerobic coverage and misses Pasteurella multocida (animal bites) and Eikenella corrodens (human bites). Use amoxicillin-clavulanate instead 5
Assuming higher doses are better: The evidence does not support routine use of high-dose regimens (>4 mg/kg TMP) for standard wound infections 2
Forgetting streptococcal coverage: For nonpurulent cellulitis or when streptococci are suspected, TMP-SMX monotherapy is inadequate 1
Adverse events: Monitor for hyperkalemia (14.3% incidence), acute kidney injury (15.7%), and hepatotoxicity, particularly with higher doses 6. Recent data also suggests increased risk of acute respiratory failure in adolescents and young adults 7.